Eric Perakslis

Eric Perakslis

Biotech executive & former Chief Information Officer and Chief Scientist, U.S. Food and Drug Administration

As a Rubenstein Fellow, Perakslis developed and led cross-campus collaborations to position Duke Health as a global leader in data science applications and training. Eric is now the Chief Science & Digital Officer at the Duke Clinical Research Institute.


Prior to joining Duke, Eric Perakslis, PhD,  served as Chief Scientific Advisor at Datavant, Lecturer in the Department of Biomedical Informatics at Harvard Medical School, and Strategic Innovation Advisor to Médecins Sans Frontières.

Eric was Senior Vice President and Head of the Takeda R&D Data Science Institute, where he built an integrated institute of more than 165 multi-disciplinary data scientists serving all aspects of biopharmaceutical R&D and digital health. Prior to Takeda, Eric was the Executive Director of the Center for Biomedical Informatics and the Countway Library of Medicine, an Instructor in Pediatrics at Harvard Medical School, and a faculty member of the Children’s Hospital Informatics Program at Boston Children’ Hospital.

During his time at HMS, Eric focused on the approval of the Department of Biomedical Informatics as a full academic department, the development of the NIH Undiagnosed Diseases Network, industry collaborations, leading the technology efforts for multiple Ebola response programs, and building active research programs in medical product development, regulatory science, and cyber security.

Prior to HMS, Eric served as Chief Information Officer and Chief Scientist (Informatics) at the U.S. Food and Drug Administration. In this role, Eric authored the first IT Strategic Plan for FDA and was responsible for modernizing and enhancing the IT capabilities as well as in silico scientific capabilities at FDA.

Prior to his time at FDA, Eric was Senior Vice President of R&D Information Technology at Johnson & Johnson Pharmaceuticals R&D and member of the Corporate Office of Science and Technology. While at J&J, Eric created and open-sourced the tranSMART clinical data system, which is now being freely used by hundreds of healthcare organizations. During his 13 years at J&J, Eric also held the posts of VP R&D Informatics, VP and Chief Information Officer, Director of Research Information Technology, and Director of Drug Discovery Research. Prior to working at J&J, Eric was the Group leader of Scientific Computing at ArQule Inc.

Eric has served on the editorial board of Cancer Today magazine and as the Associate Editor for Novel Communications for the Journal of Therapeutic Innovation and Regulatory Science. Eric has also served on Science and Technology Advisory Committees and in leadership roles for the American Society of Clinical Oncology, NuMedii, Precision for Medicine, the Survivor Advisory Board at the Cancer Institute of New Jersey, the Kidney Cancer Association, OneMind4Research, and the Scientist - Survivor program of the American Association for Cancer Research. Internationally, Eric has served as the Chief Information Officer of the King Hussein Institute for Biotechnology and Cancer in Amman, Jordan.

Eric has a PhD in chemical and biochemical engineering from Drexel University. He also holds BSChE and MS degrees in chemical engineering.

Read Full Bio

Eric Perakslis News & Events

View All News View All Events
7Feb, 2019

FDA Emergency Authorizes First At-Home, Over-The-Counter Coronavirus Test

Wednesday, December 16, 2020

WBUR Here & Now | December 16, 2020 We talk to Eric Perakslis, a faculty member at Duke University, about the first at-home, over-the-counter COVID-19 test that will be hitting shelves next month following emergency authorization by the Food and Drug Administration this week. The test, which was developed by Australian company Ellume, will give users their results…

7Feb, 2019

Data Concerns Dedevil Vaccine Rollout

Wednesday, November 18, 2020

Politico | November 18, 2020By Darius Tahir THE TECH CHALLENGE AHEAD: We’ve all heard the two blasts of good news on coronavirus vaccines. But good news can also deliver hard challenges — in this case, data to drive immunizations. … — Patient-matching and privacy: The vaccine administration campaign will have to deal with a longstanding challenge in…

7Feb, 2019

“Outbreak Informatics from Ebola to Covid-19: Lessons Learned and Unlearned" with Eric Perakslis

Zoom - Wednesday, November 11, 2020

The University of Kentucky International Society for Pharamceutical Engineering (ISPE) student organization will host a seminar related to the COVID-19 pandemic on November 11, 2020 at 5:00 p.m. The talk will be given by Eric Perakslis, Ph.D., former chief information officer and chief scientist for the U.S. Food and Drug Administration, and is titled, “Outbreak…

7Feb, 2019

Clinical Trial Software Company Hit by Massive Ransomware Attack

Zoom - Wednesday, October 7, 2020

BioSpace | October 5, 2020By Mark Terry Last week, Universal Health Services (UHS) was hit by a massive ransomware attack, which is believed to be one of the largest cyberattacks on a medical institution in the U.S. Now, Philadelphia-based software company eResearchTechnology (ERT), which offers software used in hundreds of clinical trials, has suffered a ransomware attack.…

7Feb, 2019

Learning Health Systems Based Upon Outbreak Informatics

via WebEx - Wednesday, April 15, 2020

This free WebEx presentation by Dr. Eric Perakslis is hosted by the North Carolina Biotechnology Center As the COVID-19 epidemic scales exponentially across the United States, calls for expended use of telehealth, innovative technology solutions and optimization of life-saving critical care hospital beds clearly highlight unmet needs in the American healthcare system. Dr. Perakslis will…

“The Rubenstein Fellowship confirmed my suspicion that Duke has the potential to revolutionize the perceptions and practice of translational medicine. The collaborative culture between clinicians and scientists, the non-traditional partnerships across the university, the operational capabilities of DCRI and the willingness to undertake disruptive experimentation will continue to create new models of medical progress.”
- Eric Perakslis, 2019-2021 Rubenstein Fellow